LADSTELI Trademark

Trademark Overview


On Monday, June 27, 2022, a trademark application was filed for LADSTELI with the United States Patent and Trademark Office. The USPTO has given the LADSTELI trademark a serial number of 97477187. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, November 5, 2024. This trademark is owned by Teva Pharmaceuticals USA. The LADSTELI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
ladsteli

General Information


Serial Number97477187
Word MarkLADSTELI
Filing DateMonday, June 27, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 16, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Thursday, June 30, 2022NEW APPLICATION ENTERED
Thursday, July 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 22, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, February 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 11, 2023ASSIGNED TO EXAMINER
Wednesday, April 12, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 4, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 4, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 4, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 16, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 16, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 4, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 4, 2024SOU EXTENSION 1 FILED
Thursday, January 4, 2024SOU EXTENSION 1 GRANTED
Saturday, January 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 11, 2024SOU EXTENSION 2 FILED
Monday, August 12, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, August 13, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, August 13, 2024PETITION TO REVIVE-GRANTED
Tuesday, August 13, 2024NOTICE OF REVIVAL - E-MAILED
Tuesday, August 13, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Monday, November 4, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 6, 2024SOU EXTENSION 2 GRANTED
Wednesday, November 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED